Taysha Gene Therapies (NASDAQ:TSHA) CEO Sells $649,747.75 in Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) CEO Sean Nolan sold 136,789 shares of the firm’s stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $4.75, for a total transaction of $649,747.75. Following the completion of the transaction, the chief executive officer directly owned 2,949,569 shares in the company, valued at approximately $14,010,452.75. This represents a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Taysha Gene Therapies Stock Up 0.8%

TSHA stock traded up $0.04 during midday trading on Tuesday, hitting $4.76. The company’s stock had a trading volume of 1,384,585 shares, compared to its average volume of 2,812,476. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $6.02. The firm has a market capitalization of $1.30 billion, a P/E ratio of -14.42 and a beta of 1.02. The firm has a 50-day simple moving average of $5.08 and a 200-day simple moving average of $4.07.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. As a group, equities analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Jefferies Financial Group Inc. lifted its holdings in Taysha Gene Therapies by 4,105.3% in the 2nd quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock worth $23,825,000 after buying an additional 10,068,479 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in Taysha Gene Therapies in the 2nd quarter valued at $11,178,000. Barclays PLC grew its holdings in shares of Taysha Gene Therapies by 1,042.8% in the 3rd quarter. Barclays PLC now owns 5,148,112 shares of the company’s stock worth $16,834,000 after purchasing an additional 4,697,611 shares during the last quarter. MPM Bioimpact LLC bought a new position in Taysha Gene Therapies in the second quarter valued at about $6,823,000. Finally, Vestal Point Capital LP boosted its position in shares of Taysha Gene Therapies by 83.3% during the third quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company’s stock worth $17,985,000 after purchasing an additional 2,500,000 shares in the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on TSHA. Wall Street Zen downgraded Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. JMP Securities set a $8.00 price target on Taysha Gene Therapies in a research note on Wednesday, November 5th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 target price on shares of Taysha Gene Therapies in a report on Friday, November 14th. Raymond James Financial restated a “strong-buy” rating and set a $13.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Finally, Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Taysha Gene Therapies currently has an average rating of “Moderate Buy” and an average target price of $10.67.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.